Search the phrase “GLP-1 settlement” and you will find figures, timelines and predictions. Search the federal vision loss docket for the word “settle” and you will find nothing. Across every entry on the master docket in MDL 3163 there is no mediator, no settlement conference, no settlement program, no claims administrator, no bellwether trial and no verdict. The one document that most often gets mistaken for a settlement is Case Management Order No. 15, entered August 27, 2026, which establishes a time and expense protocol and a common benefit fund — a mechanism for paying the lawyers doing shared work, not a fund that pays claimants. The distinction matters, because a claimant who believes money is already set aside will make different decisions than one who knows the case is on a 2027 motions calendar.
What a common benefit fund is
In a multidistrict proceeding, a small group of appointed leadership lawyers does work that benefits everyone: they take the company depositions, retain the general causation experts, brief the preemption motion. A common benefit fund is how that work gets paid for. The court orders a percentage to be held back from recoveries, and leadership counsel submit time and expense records for approval.
Two things follow from that. The first is that a common benefit order is a sign the court expects shared work to be substantial — which, on a docket that has just scheduled eighteen months of causation and preemption litigation, it plainly is. The second is that a common benefit fund contains no money at all unless and until there are recoveries. It is plumbing installed in advance, not water.
Why there is nothing to negotiate over yet
Mass tort settlements are priced off information, and the information that does the pricing has not been produced here. Nobody has taken the case-specific discovery. No expert has been deposed. No court has ruled on whether the plaintiffs’ general causation evidence is admissible under Rule 702, and no court has ruled on whether federal drug labeling law preempts the warning claims. Until those two rulings exist, neither side can put a number on a case with any confidence, because the range of outcomes still includes zero for every claimant and also includes a jury question in every claimant’s case.
The court said as much when it set the sequence. Case Management Order No. 12 describes the cross-cutting issues as questions that could resolve every case in the MDL, could end the Lilly defendants’ involvement, or could send the litigation on to bellwether selection with the benefit of the ruling. Those are not small forks. Settlement talks, when they happen in litigation like this, tend to follow them rather than precede them.
What the docket does contain
- A schedule, entered August 27, 2026, running from plaintiff fact sheets in September 2026 to fully briefed Rule 702 and summary judgment motions on August 31, 2027.
- A Special Discovery Master, a retired federal judge, appointed in July 2026 to hear discovery disputes first.
- Leadership counsel appointed in February 2026, and a Science Day held June 2, 2026 — a teaching session, not a hearing, at which each side explains the medicine to the judge.
- A time and expense protocol and common benefit fund, entered the same day as the schedule.
- New cases still arriving. Plaintiffs may file directly into the district, and conditional transfer orders continued through 2026.
That is the profile of a proceeding organizing itself for a fight over admissibility, not one winding down.
The honest caveat
Private negotiations are not docketed. Parties can and do talk without telling a court, and the first public sign is often an order that appears after an agreement is already in principle. So the accurate statement is narrow: there is no settlement machinery of any kind on the public record in this proceeding, and no court-supervised process for resolving these claims as a group. Anyone telling you otherwise, or quoting you a per-case figure, is describing something that does not exist in the record.
What this means if you have a claim
It means the useful work right now is evidentiary, not financial. Pharmacy records that establish when a medication was taken, and ophthalmology records that establish when the vision loss was diagnosed, are worth more to a claim today than any projection about what cases might eventually be worth. Our page on NAION claims after a GLP-1 medication sets out which records matter and why. It also means the statute of limitations in your state continues to run on its own schedule, indifferent to the pace of the federal docket.
This article is general information about how these cases work. It is not legal advice, it does not create an attorney-client relationship, and no two claims are alike. If something here sounds like your situation, the useful next step is a conversation about the facts.
